MiR-218-5p and Doxorubicin Combination Enhances Anticancer Activity in Breast Cancer Cells Through Parkin-dependent Mitophagy Inhibition

Overview

Journal Cell Death Discov

Date 2024 Mar 22

PMID 38514650

Authors

Francesco Davide Naso

Krenare Bruqi

Valeria Manzini

Valerio Chiurchiu

Mara DOnofrio

Ivan Arisi

Flavie Strappazzon

Affiliations

Soon will be listed here.

Abstract

Breast Cancer (BC) is one of the most common tumours, and is known for its ability to develop resistance to chemotherapeutic treatments. Autophagy has been linked to chemotherapeutic response in several types of cancer, highlighting its contribution to this process. However, the role of mitophagy, a selective form of autophagy responsible for damaged mitochondria degradation, in the response to therapies in BC is still unclear. In order to address this point, we analysed the role of mitophagy in the treatment of the most common anticancer drug, doxorubicin (DXR), in different models of BC, such as a luminal A subtype-BC cell line MCF7 cells, cultured in 2-Dimension (2D) or in 3-Dimension (3D), and the triple negative BC (TNBC) cell line MDA-MB-231. Through a microarray analysis, we identified a relationship between mitophagy gene expressions related to the canonical PINK1/Parkin-mediated pathway and DXR treatment in BC cells. Afterwards, we demonstrated that the PINK1/Parkin-dependent mitophagy is indeed induced following DXR treatment and that exogenous expression of a small non-coding RNA, the miRNA-218-5p, known to target mRNA of Parkin, was sufficient to inhibit the DXR-mediated mitophagy in MCF7 and in MDA-MB-231 cells, thereby increasing their sensitivity to DXR. Considering the current challenges involved in BC refractory to treatment, our work could provide a promising approach to prevent tumour resistance and recurrence, potentially leading to the development of an innovative approach to combine mitophagy inhibition and chemotherapy.

Citing Articles

Predictive Value of Gene Expression in Chemotherapy Response in Breast Cancer.

Munoz J, Lampe-Huenul N Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006048 PMC: 11859796. DOI: 10.3390/ph18020235.

sdRNA-D43 derived from small nucleolar RNA snoRD43 improves chondrocyte senescence and osteoarthritis progression by negatively regulating PINK1/Parkin-mediated mitophagy pathway via dual-targeting NRF1 and WIPI2.

Deng Z, Li C, Hu S, Zhong Y, Li W, Lin Z Cell Commun Signal. 2025; 23(1):77.

PMID: 39934774 PMC: 11817878. DOI: 10.1186/s12964-024-01975-2.

MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.

Lu X, Jin H Front Pharmacol. 2024; 15:1486783.

PMID: 39679367 PMC: 11638538. DOI: 10.3389/fphar.2024.1486783.

Mitophagy: insights into its signaling molecules, biological functions, and therapeutic potential in breast cancer.

Chen C, Xiang A, Lin X, Guo J, Liu J, Hu S Cell Death Discov. 2024; 10(1):457.

PMID: 39472438 PMC: 11522701. DOI: 10.1038/s41420-024-02226-6.

Exploring Mitochondrial Interactions with Pulsed Electromagnetic Fields: An Insightful Inquiry into Strategies for Addressing Neuroinflammation and Oxidative Stress in Diabetic Neuropathy.

Chianese D, Bonora M, Sambataro M, Sambato L, Paola L, Tremoli E Int J Mol Sci. 2024; 25(14).

PMID: 39063025 PMC: 11277522. DOI: 10.3390/ijms25147783.

References

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-42. DOI: 10.1038/nm.2919. View

Antonelli M, Strappazzon F, Arisi I, Brandi R, DOnofrio M, Sambucci M . ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy. Oncotarget. 2017; 8(13):21692-21709. PMC: 5400616. DOI: 10.18632/oncotarget.15537. View

Yan C, Luo L, Guo C, Goto S, Urata Y, Shao J . Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. Cancer Lett. 2016; 388:34-42. DOI: 10.1016/j.canlet.2016.11.018. View

Xie X, Yang Y, Wang Q, Liu H, Fang X, Li C . Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Res. 2023; 33(3):215-228. PMC: 9977947. DOI: 10.1038/s41422-022-00766-z. View

Dagda R, Zhu J, Kulich S, Chu C . Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy. 2008; 4(6):770-82. PMC: 2574804. DOI: 10.4161/auto.6458. View

AMENTA J, Hlivko T, McBee A, Shinozuka H, Brocher S . Specific inhibition by NH4CL of autophagy-associated proteloysis in cultured fibroblasts. Exp Cell Res. 1978; 115(2):357-66. DOI: 10.1016/0014-4827(78)90289-6. View

Onishi M, Yamano K, Sato M, Matsuda N, Okamoto K . Molecular mechanisms and physiological functions of mitophagy. EMBO J. 2021; 40(3):e104705. PMC: 7849173. DOI: 10.15252/embj.2020104705. View

Narendra D, Kane L, Hauser D, Fearnley I, Youle R . p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy. 2010; 6(8):1090-106. PMC: 3359490. DOI: 10.4161/auto.6.8.13426. View

Amin N, Bai G, Klug J, Bonanomi D, Pankratz M, Gifford W . Loss of motoneuron-specific microRNA-218 causes systemic neuromuscular failure. Science. 2015; 350(6267):1525-9. PMC: 4913787. DOI: 10.1126/science.aad2509. View

10.

Andres A, Tucker K, Thomas A, Taylor D, Sengstock D, Jahania S . Mitophagy and mitochondrial biogenesis in atrial tissue of patients undergoing heart surgery with cardiopulmonary bypass. JCI Insight. 2017; 2(4):e89303. PMC: 5313075. DOI: 10.1172/jci.insight.89303. View

11.

Sempere L, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V . Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004; 5(3):R13. PMC: 395763. DOI: 10.1186/gb-2004-5-3-r13. View

12.

Bertolin G, Ferrando-Miguel R, Jacoupy M, Traver S, Grenier K, Greene A . The TOMM machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance. Autophagy. 2013; 9(11):1801-17. DOI: 10.4161/auto.25884. View

13.

Vianello C, Cocetta V, Catanzaro D, Dorn 2nd G, De Milito A, Rizzolio F . Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. Cell Death Dis. 2022; 13(4):398. PMC: 9033831. DOI: 10.1038/s41419-022-04741-9. View

14.

Ahmadinejad F, Mowla S, Honardoost M, Arjenaki M, Moazeni-Bistgani M, Kheiri S . Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis. Tumour Biol. 2017; 39(8):1010428317698362. DOI: 10.1177/1010428317698362. View

15.

Hu Y, Xu K, Yague E . miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat. 2015; 151(2):269-80. DOI: 10.1007/s10549-015-3372-9. View

16.

Sritharan S, Sivalingam N . A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021; 278:119527. DOI: 10.1016/j.lfs.2021.119527. View

17.

Lemasters J . Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 2005; 8(1):3-5. DOI: 10.1089/rej.2005.8.3. View

18.

Tay S, Yeo C, Chai C, Chua P, Tan H, Ang A . Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem. 2010; 285(38):29231-8. PMC: 2937954. DOI: 10.1074/jbc.M110.108241. View

19.

Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z . Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014; 35(14):4333-44. DOI: 10.1016/j.biomaterials.2014.02.006. View

20.

Menon A, Abd-Aziz N, Khalid K, Poh C, Naidu R . miRNA: A Promising Therapeutic Target in Cancer. Int J Mol Sci. 2022; 23(19). PMC: 9569513. DOI: 10.3390/ijms231911502. View